Cagrilintide used for the treatment of obesity and type 2 diabetes Innovent Dosed First Participant in Phase 3 Clinical Study (GLORY 2) of Mazdutide (IBI362) Higher Dose 9 mg in Chinese Adults with Obesity Once weekly mazdutide, a glucagon like peptide 1 and glucagon receptor dual agonist, provided clinically relevant reduction in body weight in Chinese adults with obesity or overweight. Full GLORY 1 trial results: https: nej.md 4koUvaP Emerging incretin and multi agonist based treatments the continued refinement and continuous expansion of a potent therapeutic armamentarium for cardio kidney liver metabolic diseases and beyond Metabolism Clinical and Experimental Cagrilintide acetate CAS 1415456 99 3 Order from Adipogen Life Sciences AMYR and CTR Agonist Cagrilintide medication for weight loss and appetite control